



Quality of Science, Speed of Execution,  
Passion for Improving the lives of Patients

CORPORATE FACT SHEET | FEBRUARY 2012

## SYNTA OVERVIEW

Synta Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease. Synta has a unique chemical compound library, an integrated discovery engine, and a pipeline of small molecule drug candidates with novel chemical structures and distinct mechanisms of action. All drug candidates were invented internally by Synta scientists using our compound library and discovery capabilities.

## COMPANY HIGHLIGHTS

**Strong pipeline of novel internally-developed candidates in cancer and inflammatory disease** including: **ganetespib**, a potent, second-generation, small molecule Hsp90 inhibitor currently being studied in more than 20 cancer trials; **elesclomol**, a first-in-class inhibitor of mitochondrial energy production; **STA-9584**, a dual-acting vascular disrupting agent; an oral/topical **IL-12/IL-23** inhibitor program for autoimmune and inflammatory diseases; and a **CRACM** ion channel inhibitor program for chronic inflammatory diseases and transplant rejection. All programs are 100% owned by Synta.

**Unique drug discovery engine** that has generated all Synta compounds to date and continues to generate promising, novel, small-molecule drug candidates. Platform based on unique chemical compound library; high throughput screening and in vivo modeling capabilities; medicinal, computational, analytic, process-development chemistry expertise; in vitro and in vivo toxicology and DMPK experience.

**Strong financial position** with approximately \$50.7 million in cash at Q3 2011. Completed \$28.6M public offering in January 2012. Additionally, \$35 million equity line of credit (Azimuth) and \$15 million loan (GE Capital) in place as of October 2010.

**Strong intellectual property position** with portfolio of over 700 issued or pending patents. All Synta compounds currently in clinical trials represent novel chemical structures protected by issued or allowed composition of matter patents and related structure, mechanism, formulation, manufacturing, and administration patents.

This document may contain forward-looking statements about Synta Pharmaceuticals Corp. including statements relating to the timing and progress of our clinical and preclinical programs. These forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those risks and uncertainties described under "Risk Factors" in our Form 10-K for the year ended December 31, 2010 as filed with the Securities and Exchange Commission. Synta undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

## AT-A-GLANCE

As of February 1, 2012  
NASDAQ: SNTA  
Recent price: \$4.85  
52-week range: \$3.02 - \$6.27  
Shares outstanding: 56,498,350  
Market Cap: \$274.0 million  
Analyst Coverage: BMO,  
Canaccord, Edison, Lazard, MLV,  
Rodman & Renshaw, Roth,  
ThinkEquity

## SENIOR MANAGEMENT

Safi Bahcall, Ph.D.  
President, Chief Executive Officer

Keizo Koya, Ph.D.  
SVP, Pharmaceutical Development

Amar Singh, M.B.A.  
SVP, Chief Business Officer

Vojo Vukovic, M.D., Ph.D.  
SVP, Chief Medical Officer

Keith Ehrlich, C.P.A.  
VP, Chief Financial Officer

Iman El-Hariry, M.D., Ph.D.  
VP, Clinical Research

Arthur McMahon  
VP, Human Resources

Wendy Rieder, Esq.  
VP, General Counsel

Ilker Yalcin, PhD, MBA  
VP, Biostatistics & Data  
Management

## IR CONTACT

Rob Kloppenburg  
VP, Investor Relations and  
Corporate Communications  
(781) 541-7125  
ir@syntapharma.com

Synta Pharmaceuticals Corp.  
45 Hartwell Avenue  
Lexington, MA 02421  
Tel: (781) 274-8200  
Fax: (781) 274-8228

ONCOLOGY	LEAD OPT	PRE- CLINICAL	PHASE I	PHASE II	PHASE III
<b>Ganetespib (Hsp90i)</b>					
<i>Ph 2b/3 NSCLC (2L, +D)</i>	[Progression bar from LEAD OPT to PHASE II]				
<i>ALK+ NSCLC</i>	[Progression bar from LEAD OPT to PHASE II, labeled 2012]				
<i>Breast (Her2+, TNBC)</i>	[Progression bar from LEAD OPT to PHASE II, labeled 2012]				
<i>AML (1L, +Ara-C)</i>	[Progression bar from LEAD OPT to PHASE II, labeled 2012]				
<i>Others (NSCLC, breast, colon, gastric, GIST, hepatic, pancreatic, melanoma, prostate)</i>	[Progression bar from LEAD OPT to PHASE II]				
<i>Additional combinations</i>	[Progression bar from LEAD OPT to PHASE I]				
<b>Elesclomol (mitochondria)</b>					
<i>Ovarian</i>	[Progression bar from LEAD OPT to PHASE II]				
<i>AML</i>	[Progression bar from LEAD OPT to PHASE I]				
<b>STA-9584 (VDA)</b>					
<b>INFLAMMATION</b>					
<b>CRAC inhibitors</b>	[Progression bar from LEAD OPT to PHASE I]				
<b>Hsp90i - inflamm</b>	[Progression bar from LEAD OPT to PHASE I]				
<b>IL-12/23 inhibitors</b>	[Progression bar from LEAD OPT to PHASE I]				

#### ONCOLOGY:

- Ganetespib:** Potent, second-generation, small molecule drug candidate that inhibits heat shock protein 90 (Hsp90), a chaperone regulating numerous proteins that drive proliferation in cancer cells. Up to 100x more potent than first-generation Hsp90 inhibitors (17-AAG). Over 450 patients treated to date across a broad range of trials in solid and hematologic cancers. Clear evidence of single-agent clinical activity in multiple tumor types including ALK+ NSCLC and breast cancer. Favorable safety profile; absence of serious liver or common ocular toxicities seen with other Hsp90 inhibitors. A Phase 2b/3 trial in combination with docetaxel in 2<sup>nd</sup>-line, advanced NSCLC is ongoing, global trials in ALK+ NSCLC and breast cancer are initiating.
- Elesclomol:** Triggers apoptosis through disrupting mitochondrial energy metabolism of cancer cells. Established that LDH and certain other markers of cancer cell metabolism are predictive of elesclomol anti-cancer activity. In three randomized trials, involving over 800 patients, clinical activity was shown in the marker positive patient population. A GOG-sponsored Phase 2 trial in ovarian cancer in combination with paclitaxel and a Phase 1 trial in AML are ongoing.
- STA-9584:** A dual-acting vascular disrupting agent that has demonstrated potent anti-tumor activity in preclinical models, including activity against large, established tumors. Differentiated activity and improved therapeutic index compared to the first generation of VDAs.

#### INFLAMMATION:

- Calcium release activated calcium modulator (CRACM) ion channel inhibitors:** Compounds that modulate the calcium signaling pathway in immune cells that drives inflammatory responses, including secretion of TNF $\alpha$  and IL-2. Synta CRACM inhibitors have shown potent *in vivo* inhibition of TNF $\alpha$  and IL-2; activity in immune disease models including rheumatoid arthritis, psoriasis, and inflammatory bowel diseases; and an acceptable safety profile.
- IL 12/ 23 Inhibitors:** Novel, small molecule drug candidates that inhibit the production of the cytokines interleukin-12 (IL-12), and interleukin-23 (IL-23), down-regulating inflammation pathways that drive certain autoimmune and inflammatory diseases.

